Outcome and Prognostic Factors of High-Risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation-Reference-Cited by-同舟云学术

Outcome and Prognostic Factors of High-Risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Published:2019-06-07 Issue: Volume:24 Page:328-340
ISSN:2329-0358
Container-title:Annals of Transplantation
language:en
Short-container-title:Ann Transplant

Author:

Zhu Cheng-ying¹,Chen Guo-feng¹,Zhou Wei¹,Hou Cheng²,Wang Xiao-kai³,Wang Fei-yan¹,Yang Nan²,Wang Li⁴,Fang Shu²,Luo Lan²,Guan Li-xun²,Zhang Ran²,Liu Yu-chen²,Dou Li-ping²,Gao Chun-ji¹

Affiliation:

1. School of Medicine, Nankai University, Tianjin, China (mainland)

2. Department of Hematology, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China (mainland)

3. Department of Orthopedics, Xiqing Hospital, Tianjin, China (mainland)

4. Department of Hematology and Oncology, Laoshan Branch, No. 401 Hospital of Chinese People’s Liberation Army (PLA), Qingdao, Shandong, China (mainland)

Publisher

International Scientific Information, Inc.

Subject

Transplantation,General Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic Hematopoietic Stem Cell Transplantation Can Improve Prognosis of Extramedullary Infiltration Positive t(8;21) Acute Myeloid Leukemia;Annals of Transplantation;2023-11-07

2. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation presenting as pericardial effusion;Blood Science;2023-10

3. The results of therapy with venetoclax, daratumumab and plerixafor as part of the conditioning regimen in chemotherapy-refractory acute leukemia in children;Pediatric Hematology/Oncology and Immunopathology;2023-09-30

4. Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia;Frontiers in Immunology;2023-06-22

5. Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia;Transplantation and Cellular Therapy;2023-02